Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)

Inclusion Criteria: * A signed written Informed Consent * Presence of typical atrial flutter (cavotricuspid isthmus dependent) * If subjects are receiving antiarrhythmic drug therapy (Class I or Class III AAD)for an arrhythmia other than typical atrial flutter, then the subject needs to be controlled on their medication for at least 3 months. If the subject had typical atrial flutter before starting the AAD(s) (Class I or Class III) and then subsequently had another arrhythmia (i.e. atrial fibrillation), then the 3 month AAD criteria will not apply. * One documented occurrence of the study arrhythmia documented by ECG, Holter, telemetry strip, or transtelephonic monitor within the past 6 months * In good physical health * 18 years of age or older * Agree to comply with follow-up visits and evaluation Exclusion Criteria: * Prior typical atrial flutter ablation treatment * Pregnancy * Atypical flutter or scar flutter(non-isthmus dependent) * Significant coronary heart disease or heart failure; that is unstable angina pectoris and/or uncontrolled congestive heart failure (NYHA Class III or IV) at the time of enrollment * A recent myocardial infarction within 3 months of the intended procedure date * Permanent coronary sinus pacing lead * Tricuspid valvular disease requiring surgery and/or a prosthetic tricuspid heart valve (i.e. significant) * Evidence of intracardiac thrombus or a history of clotting disorders * Participation in another investigational study * Cardiac surgery within 1 month of the intended procedure date * Allergy or contraindication to Heparin